Furthermore, a nationwide, retrospective cohort study including more than one million drug-naïve patients with T2D found that, during a 15-year follow up period, treatment with GLP-1 RAs was associated with a decreased risk of colorectal cancer compared with insulin, metformin, SGLT2-i, sulfonylureas and thiazolidinediones [134]. This evidence concerns the gene INS and type 2 diabetes mellitus.